Pembrolizumab plus lenvatinib in advanced endometrial cancer: case report and systematic review of lung toxicity

BACKGROUND: The optimal strategy for the treatment of recurrent and/or advanced endometrial cancer is still undefined. Recently, despite the lack of any predictive biomarker, the combination of pembrolizumab with lenvatinib has improved survival outcomes. We here report the long-term management of l...

Descripción completa

Detalles Bibliográficos
Autores principales: Staropoli, Nicoletta, Salvino, Angela, Falcone, Federica, Farenza, Valentina, Costa, Martina, Rossini, Giacomo, Manti, Francesco, Crispino, Antonella, Riillo, Caterina, Ciliberto, Domenico, Arbitrio, Mariamena, Tassone, Pierfrancesco, Tagliaferri, Pierosandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10363977/
https://www.ncbi.nlm.nih.gov/pubmed/37492471
http://dx.doi.org/10.3389/fonc.2023.1145986

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10363977/
https://www.ncbi.nlm.nih.gov/pubmed/37492471
http://dx.doi.org/10.3389/fonc.2023.1145986

Ejemplares similares